Alnylam Pharmaceuticals, Inc. (ALNY)
240.68
+3.58
(+1.51%)
USD |
NASDAQ |
Aug 31, 16:00
240.68
0.00 (0.00%)
After-Hours: 20:00
Alnylam Pharmaceuticals Cash from Operations (TTM) : 885.89M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 885.89M |
| March 31, 2026 | 688.98M |
| December 31, 2025 | 498.16M |
| September 30, 2025 | 239.94M |
| June 30, 2025 | -41.46M |
| March 31, 2025 | -47.11M |
| December 31, 2024 | -8.312M |
| September 30, 2024 | 56.56M |
| June 30, 2024 | 372.26M |
| March 31, 2024 | 189.12M |
| December 31, 2023 | 104.16M |
| September 30, 2023 | 1.973M |
| June 30, 2023 | -472.72M |
| March 31, 2023 | -536.56M |
| December 31, 2022 | -541.27M |
| September 30, 2022 | -559.44M |
| June 30, 2022 | -578.19M |
| March 31, 2022 | -577.23M |
| December 31, 2021 | -641.69M |
| September 30, 2021 | -614.70M |
| June 30, 2021 | -590.99M |
| March 31, 2021 | -604.46M |
| December 31, 2020 | -614.96M |
| September 30, 2020 | -687.80M |
| June 30, 2020 | -760.10M |
| Date | Value |
|---|---|
| March 31, 2020 | -336.08M |
| December 31, 2019 | -278.43M |
| September 30, 2019 | -232.90M |
| June 30, 2019 | -204.08M |
| March 31, 2019 | -595.46M |
| December 31, 2018 | -562.62M |
| September 30, 2018 | -515.20M |
| June 30, 2018 | -459.76M |
| March 31, 2018 | -438.12M |
| December 31, 2017 | -382.79M |
| September 30, 2017 | -358.08M |
| June 30, 2017 | -335.25M |
| March 31, 2017 | -324.41M |
| December 31, 2016 | -307.70M |
| September 30, 2016 | -282.43M |
| June 30, 2016 | -261.26M |
| March 31, 2016 | -246.51M |
| December 31, 2015 | -189.14M |
| September 30, 2015 | -172.71M |
| June 30, 2015 | -159.05M |
| March 31, 2015 | -150.22M |
| December 31, 2014 | -165.64M |
| September 30, 2014 | -151.38M |
| June 30, 2014 | -132.38M |
| March 31, 2014 | -109.36M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Ionis Pharmaceuticals, Inc. | -496.43M |
| BridgeBio Pharma, Inc. | -434.37M |
| Regeneron Pharmaceuticals, Inc. | 4.681B |
| Vertex Pharmaceuticals, Inc. | 4.293B |
| Pfizer Inc. | 13.40B |